Today it was reported that the Chairman & CEO of Athersys (ATHX – Research Report), Gil Van-Bokkelen, exercised options to buy 20,000 ATHX shares at $1.28 a share, for a total transaction value of $25.6K.
Following this transaction Gil Van-Bokkelen’s holding in the company was increased by 1.27% to a total of $2.03 million.
Currently, Athersys has an average volume of 243.81K. The company has a one-year high of $2.23 and a one-year low of $1.20.
Starting in October 2018, ATHX received 7 Buy ratings in a row.
Gil Van-Bokkelen’s trades have generated a 21.2% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.